COPD patients who cannot effectively operate or benefit from a dry powder or metered dose inhaler are prescribed nebulized medicines. These patients with more severe COPD can receive a full dose with a nebulizer, regardless of disease state, because all that is required is tidal (normal) breathing. However, medicines currently available for nebulization require 2-4 doses per day and long treatment times (10-15 minutes per dose) using conventional table top jet nebulizers, often leading to poor compliance and thus clinical outcomes. Additionally, LAMAs are considered first-line therapy for moderate-to-severe COPD, but no formulation of a LAMA is available for nebulization.
EP-101 can be the first LAMA approved for a nebulizer, and it is being developed in combination with an Investigational eFlow device – a portable nebulizer providing short treatment times – significantly improving the standard of care for the large underserved subpopulation of COPD patients not adequately treated by conventional inhalers or nebulizers.
"We are very encouraged by the outcomes of this study in COPD," said Bill Gerhart, President and CEO at Elevation. "These positive results bring us closer to achieving our goal of validating a new standard of care for COPD that significantly improves patient compliance and clinical outcomes."
Based on the positive results of this Phase 2a study, Elevation drew down a $17 million second tranche of its Series A financing and has initiated a Phase 2b study of EP-101 for which top-line results are projected to be available by the end of the first quarter of 2012. All the or
|SOURCE Elevation Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved